Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported that Chief Scientific Officer Daniel S. Lorrain executed a series of stock transactions between July 8 and July 9, 2026. Lorrain sold 1,040 shares of the company’s Class A Common Stock, resulting in total proceeds of $16,640. These sales were conducted in accordance with a 10b5-1 trading plan that Lorrain adopted on September 23, 2025. The transactions were scheduled under this pre-arranged framework, which is designed to facilitate trading in compliance with insider trading regulations.
Before selling the shares, Lorrain exercised stock options to acquire 1,040 shares of Class A Common Stock at an exercise price of $1.01 per share, totaling $1,050. The options involved in this exercise were fully vested and exercisable, with an expiration date set for February 24, 2030. The option exercises were also executed under the same 10b5-1 trading plan. Following the completion of these transactions, Lorrain’s direct holdings in Contineum Therapeutics Class A Common Stock amounted to 135,202 shares. Additionally, 10,110 shares are held indirectly by his spouse.
The stock sale activity occurs as CTNM shares trade near their 52-week high of $16.91. Over the past year, the stock has delivered a return of 283%. Despite this strong performance, InvestingPro analysis indicates that the stock appears slightly overvalued at current levels when compared to its fair value estimate. Investors may consider additional financial metrics and analysis to evaluate the investment potential of CTNM.
In other recent developments, Contineum Therapeutics has released key findings regarding its drug candidate PIPE-791. The company published a manuscript in the Journal of Medicinal Chemistry, which details the discovery and characterization of PIPE-791, an LPAR1 antagonist designed to treat fibrotic conditions. The compound is characterized by a chemical structure that enables slow on-off binding rates and sustained target coverage. Furthermore, Contineum reported topline data from a phase 1b trial of PIPE-791, which focused on chronic osteoarthritis pain and chronic low back pain. This trial was randomized, double-blind, and placebo-controlled, involving 43 patients. Participants received a 10mg oral dose of PIPE-791 once daily over a four-week crossover period. These developments represent significant progress in Contineum’s research and clinical efforts related to its pipeline candidates.